Background: The co-existence at diagnosis of follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL) components (FL/DLBCL) has been considered a transformed lymphoma and accordingly treated although clinicobiological information on these patients is scarce. The aim of this study was to analyze the initial features and outcome of FL/DLBCL patients in the rituximab era.
Introduction
Follicular lymphoma (FL) is the second most common lymphoma in Western countries, comprising 20% of cases [1, 2] . FL is typically an indolent disease with prolonged survival, but characterized by a continuous pattern of relapses. Histological transformation into a more aggressive lymphoma occurs in a small proportion of patients. This event implies a very adverse prognosis [3, 4] . Different genetic abnormalities, including TP53 alterations, have been described in transformed lymphoma. In addition, mutational status of some genes, including NOTCH, has been related to higher risk of transformation [5, 6] . Whereas DLBCL usually appears during the evolution of FL, sometimes it is possible to identify a significant DLBCL component at FL diagnosis. The co-existence of both FL and DLBCL components (FL/DLBCL) in the same biopsy has been considered as 'transformed lymphoma at diagnosis' [7] or 'early transformation' [8] . However, others consider FL/DLBCL a 'composite lymphoma' [9] . In any case, treatment of transformed lymphoma is based on aggressive lymphoma-type immunochemotherapy, often followed by intensification if the response is favorable and the patient is in good condition [10] [11] [12] . This approach is frequently used for FL/DLBCL despite the scarcity of studies focused on this group [8, 9] . In this setting, the aim of the present study was to analyze the clinicobiological characteristics, treatment, response and outcome of patients diagnosed with FL/DLBCL in a single institution. We also compared the outcome of FL/DLBCL patients with that of patients diagnosed with pure FL or de novo DLBCL during the same period of time.
Patients and methods

Patients
In total, 878 patients consecutively diagnosed with either FL, DLBCL or FL/DLBCL from 2002 to 2015 in a single institution were included, the only criterion being the availability of histological material. All patients were treated in the rituximab era. The histological distribution was as follows: FL 1, 2 or 3a, 320 cases, FL 3 b, 8 cases, DLBCL, 510 cases. In addition, 40 patients (16 M/24 F; median age, 65 years) showed a composite pattern considered FL/DLBCL. Main initial features are described in supplementary Table S1 , available at Annals of Oncology online. All patients gave informed consent according to the declaration of Helsinki and the ethical standards of the Ethic Committee of the Hospital Clínic de Barcelona.
Definition of FL/DLBCL: histological and molecular studies
The diagnosis of FL and DLBCL was established according to the criteria described in the updated World Health Organisation (WHO) classification [2] . The definition of FL/DLBCL was based on the presence of a variable DLBCL component in the lymph node biopsy of a patient otherwise diagnosed with FL. According to WHO recommendations, the DLBCL component was defined as an area of large cells in sheets lacking follicular architecture assessed by staining for follicular dendritic cells (CD21 or CD23). Histological slides were reviewed by KK, AM, OB or EC in order to confirm the diagnosis. See supplementary Table S2 , available at Annals of Oncology online for further information. FISH using split signal probes for BCL2, BCL6 and MYC genes was carried out as described previously [13] .
COO classification in either germinal center B-cell like DLBCL (GCB DLBCL), activated B-cell like DLBCL (ABC DLBCL) or unclassified was determined in 116 DLBCL and in 29 FL/DLBCL. In 60 cases, gene expression was assessed using Human Genome U133 plus 2.0 arrays (Affymetrix) as described previously [14] . Other 85 tumors were classified using the Lymph2Cx assay by means of NanoString technology [15] .
Mutational status of NOTCH1 and NOTCH2 genes was analyzed as described previously [16] 
Staging, treatment, response and outcome
Staging was carried out according to standard procedures [17] . Data recorded are detailed in supplementary material, available at Annals of Oncology online. According to institutional guidelines, FL/DLBCL patients were treated as de novo DLBCL. Response was assessed according to conventional criteria [17] and definitions of complete response and partial response are indicated in the supplementary material, available at Annals of Oncology online. Overall survival (OS) and progression-free survival (PFS) were calculated according to standard definitions. 17 
Statistical analysis
Differences among patient subgroups were assessed by using the chisquare and Student's t-test, or nonparametric tests when appropriate. The actuarial survival analysis was carried out by the Kaplan-Meier method and the differences assessed by the log-rank test. To evaluate the prognostic impact of different variables in response to therapy, PFS and OS, multivariate analyses were carried out with the step-wise proportional hazards model (Cox model). P values <0.05 were considered statistically significant.
Results
Histological and genetic features
In total, 328 patients were diagnosed with FL [2] (grade 1, 78 cases; grade 2, 161; grade 3a, 55; and grade 3b, 8; in 26 patients, the grade could not be determined), 510 with DLBCL and 40 with FL/DLBCL. The latter group showed the following grading of the FL component: grade 1, 1 case (2.5%); grade 2, 5 cases (12.5%); grade 3a, 22 cases (55%) and grade 3 b, 12 cases (30%). The amount of the DLBCL component ranged from 5% to 95%. Supplementary Figure S1 , available at Annals of Oncology online, shows the proportion of DLBCL component in FL/DLBCL cases. In Table 1 , information on BCL2, BCL6 and MYC rearrangement is listed, as well as BCL2, BCL6 and MYC expression. No significant differences were seen between FL 1-3a/DLBCL and FL 3 b/ DLBCL in terms of BCL6 or MYC rearrangements. The lower proportion of BCL2 rearrangement and CD10 expression for FL 3 b/DLBCL cases did not reach statistical significance. Ki67 expression was higher in FL 3 b/DLBCL. COO was determined in 145 cases (FL/DLBCL, 29; DLBCL, 116). The distribution is detailed in supplementary Table S1 , available at Annals of Oncology online. Among FL/DLBCL cases, 25 (86%) were of GCB origin, 3 (10%) ABC and 1 (4%) unclassified (supplementary Table S4 , available at Annals of Oncology online). Mutational status of NOTCH 1-2 is shown in the supplementary Table S5 , available at Annals of Oncology online. Overall, 10% of FL/DLBCL patients showed NOTCH1 or NOTCH2 mutations, with this figure being not significantly different from the other groups (2% in FL and 8% in DLBCL).
Clinical picture, treatment and outcome of patients with FL/DLBCL
In supplementary Table S1 , available at Annals of Oncology online, the main clinical features of the 40 FL/DLBCL patients are listed. Bone marrow biopsies from the 13 FL/DLBCL cases with bone marrow positive showed infiltration by small cells in 12 cases and by large cells in 1. No significant differences were found in the initial characteristics according to the amount of DLBCL component or the histological grading of FL component (supplementary Tables S6 and S7 , available at Annals of Oncology online). Positron emission tomography/computed tomography was available in 30 cases of FL/DLBCL. All cases shown some degree of glucose uptake with a median SUVmax of 9.8 . No significant differences in SUVmax were observed between FL 1-3a/ DLBCL and FL 3 b/DLBCL. In addition, median SUVmax for FL/DLBCL was similar to that of DLBCL cases.
Thirty-nine of 40 FL/DLBCL patients were treated with DLBCL-like therapy, including R-CHOP regimen in 34 cases (85%) ( Table 2) . One additional patient refused therapy. Twenty-six (65%) patients reached complete response. According to our institutional guidelines, no autogeneic stemcell transplantation (ASCT) was carried out as intensification after the first-line treatment. Although not contemplated in the guidelines, three FL/DLBCL patients received maintenance with rituximab.
After a median follow-up of 5 years for surviving patients, 15 patients have relapsed with a 5-year PFS of 55% [95% confidence interval (CI), 40% to 70%) (Figure 1 ). Relapse was nodal in all cases and only two patients showed extranodal involvement. Six of 15 relapsed patients had sequential biopsies showing the following histology: FL 1-3a (three cases), FL/DLBCL (two cases) and DLBCL (one case). In supplementary Table S8 , available at Annals of Oncology online, the histological findings at relapse are detailed for all the groups.
Ten FL/DLBCL patients died during the follow-up with a 5-year OS of 73% (95% CI, 57% to 89%) ( Figure 1 The median number of delivered cycles was 6 (2-6).
CI, confidence interval; FL, follicular lymphoma; FL/DLBCL, FL with a component of DLBCL; DLBCL, diffuse large B-cell lymphoma; R-CHOP, rituximab, cyclophosphamide, doxorubicine, vincristine and prednisone; R-CVP, rituximab, cyclophosphamide, vincristine and prednisone; CR, complete response; PR, partial response; PFS, progression free survival; OS, overall survival; NS, not significant. Figure  2A ), whereas 5-year OS for FL 1-3a/DLBCL versus FL 3 b/DLBCL was of 92% versus 38%, respectively (P ¼ 0.001) ( Figure 2B ). In addition, PFS and OS curves according to the amount of DLBCL component are depicted in Figure 2C and D, showing no differences. Finally, GCB FL/DLBCL patients had a significantly better outcome than ABC FL/DLBCL (5-year PFS, 60% versus 33%, P ¼ 0.04 and 5-year OS, 70% versus 40%, P ¼ 0.018) ( Figure 2E and F).
International Prognostic Index (FLIPI). The outcome of the 40 FL/DLBCL patients was analyzed according to the histological grade of FL [FL 1-3a/DLBCL (28 cases) versus FL 3 b/DLBCL (12 cases)]. Differences in terms of PFS were not significant (
Comparison of FL/DLBCL with FL and DLBCL
Compared with DLBCL cases, patients with FL/DLBCL showed more frequently ambulatory performance status, primary nodal origin and advanced stage (P < 0.03 in all cases). On the contrary, FL/DLBCL patients had an intermediate position between FL 1-3a and DLBCL cases regarding B-symptoms, bone marrow infiltration, hemoglobin and serum lactate dehydrogenase (supplementary Table S1 , available at Annals of Oncology online).
Response to therapy for 829 evaluable patients is shown in Table 2 . The proportion of primary refractory cases was significantly higher in FL/DLBCL than in FL 1-3a patients (20% versus 5%; P ¼ 0.002) and similar to that of DLBCL patients (23%). After a median follow-up of 5.7 years for surviving patients, 343 patients experienced relapse/progression, with a 5-year PFS of 65%, 55% and 50% for FL 1-3a, FL/DLBCL and DLBCL groups, respectively. No significant differences were found in PFS between the FL/DLBCL group and the others (Table 2; Figure 3A) .
Overall, 278 patients eventually died, including 57 FL, 10 FL/ DLBCL and 211 DLBCL, being progression the most frequent cause of death in the three groups. Variables predicting OS for FL and DLBCL patients were the standard and are detailed in the supplementary Table S9 , available at Annals of Oncology online. OS by histological type is shown in Table 2 and depicted in Figure  3B . FL/DLBCL patients had a trend toward a shorter OS than FL 1-3a (73% versus 85%; P ¼ 0.09) and longer than DLBCL (73% versus 63%, P ¼ 0.06). Taking the FL group as the reference, the hazard ratios for DLBCL and FL/DLBCL groups in the Cox model were 2.97 (P < 0.001) and 1.69 (P ¼ 0. 
Discussion
A non-negligible proportion of patients with FL show at diagnosis a relevant DLBCL component in the lymph node biopsy although the biological significance and clinical implications of this finding remain unclear. This situation has received different interpretations including a transformation at diagnosis of a previously undiagnosed FL [7, 8] , or a composite lymphoma [9] . In order to avoid biases, in this study aimed at the characterization of this group, we have included all patients consecutively diagnosed with FL or DLBCL in a single institution. After histology review, 40 cases (12% of FLs) corresponded to this borderline situation, including 12 cases FL 3 b/DLBCL, although FL 3 b is considered closer to DLBCL [18, 19] . Concomitant DLBCL was more common in FL 3 b (56% of FL 3 b showed DLBCL Original article Annals of Oncology component) and 3a (28%) than in FL 1-2 (1%), in concordance to previous reports [20] . The main conclusion of this article is that, when treated as aggressive lymphomas (i.e. R-CHOP-like regimens), patients with FL/DLBCL have an outcome definitely not worse than that of de novo DLBCL. Few studies, mainly in the pre-rituximab era, have addressed this issue previously. Thus, patients with a diffuse component >50% in a biopsy showing FL grade 3 had a poorer outcome than those with FL pure grade 3, but similar to DLBCL [21] . Alternatively, in patients with DLBCL, the presence of low- grade component was associated with shorter PFS, but similar OS [7] . In a different setting, the presence of DLBCL component in patients with 'low-grade lymphoma' was not associated with a worse outcome compared with DLBCL [22, 23] . Some studies on transformed FL included patients in whom histological transformation took place at diagnosis: these patients had an outcome similar to DLBCL cases [8, 9, 24] . More recently, a study showed that FL/DLBCL patients had better prognosis than patients with FL who eventually suffered transformation [9] . In the present study, we observed that FL/DLBCL patients had intermediate features between FL and DLBCL. The outcome was somewhat better than that of de novo DLBCL and considerably more favorable than expected for transformed FLs [25] . Adriamycin containing immunochemotherapy is the standard regimen for any lymphoma with high-grade component, including FL/DLBCL, FL 3 b or transformed FL. Whether or not ASCT should be carried out in FL/DLBCL patients is the most relevant question in the clinical practice. Few data are available particularly in the setting of clinical trials, since these patients are usually excluded. In a recent study [8] , 36 patients diagnosed with 'early transformation' (situation more or less equivalent to FL/DLBCL) and treated with immunochemotherapy following by ASCT had better OS than those with 'late transformation' who received the same treatment. In our series, FL/DLBCL patients were treated as DLBCL with no further ASCT. With this approach, the outcome of our patients was better than de novo DLBCL. Taking together, all these data strongly suggest that FL/DLBCL patients should be treated with immunochemotherapy, but that intensification with upfront ASCT is not necessary nowadays. It is well known that COO assignment is important to predict prognosis and response to targeted therapy in de novo DLBCL [14] . To our knowledge, this is the first study describing the COO in FL/DLBCL patients. Eighty-six percent were of GCB phenotype and 10% ABC subtype, with these figures being different from de novo DLBCL, but similar to transformed FL [26, 27] . Interestingly, COO had prognostic impact in FL/DLBCL patients showing that GCB subtype had better outcome than ABC. These findings are important as they suggest that treatment might be tailored to underlying biology in order to reverse the adverse outcome associated with ABC phenotype.
Trying to further characterize the FL/DLBCL group, we determined the mutational status of NOTCH1-2. Mutations of NOTCH have been identified in several mature B-cell neoplasms, including FL and DLBCL. Our group has previously reported NOTCH1-2 mutations in 6% of FLs characterized by female sex, splenic involvement and presence of DLBCL component [16] . In addition, in CLL, we and others [5, 6] have related NOTCH mutations with higher risk of histological transformation. More recently, NOTCH mutation was found more frequently in cases with low-grade component [28] . However, in our FL/DLBCL cases, although the proportion of NOTCH1-2 mutations was slightly higher than in FL, the difference did not reach statistical significance.
In summary, the presence of a DLBCL component in a FL biopsy at diagnosis is an infrequent situation, but that should be diagnosed. The prognosis of these patients is not worse than that of de novo DLBCL. These cases should be treated with immunochemotherapy as aggressive lymphomas, but intensification with ASCT seems not necessary. The biological insights of FL/DLBCL warrants further clinicobiological studies. 
